Vident Investment Advisory LLC Invests $417,000 in Danaher Co. (DHR) Stock

Vident Investment Advisory LLC acquired a new position in Danaher Co. (NYSE:DHR) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 4,856 shares of the conglomerate’s stock, valued at approximately $417,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in DHR. Flossbach Von Storch AG lifted its stake in Danaher by 44.7% in the 2nd quarter. Flossbach Von Storch AG now owns 5,782,019 shares of the conglomerate’s stock worth $487,945,000 after purchasing an additional 1,785,810 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in Danaher by 16,410.0% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,485,901 shares of the conglomerate’s stock worth $125,395,000 after purchasing an additional 1,476,901 shares in the last quarter. Findlay Park Partners LLP lifted its stake in Danaher by 52.9% in the 3rd quarter. Findlay Park Partners LLP now owns 4,117,348 shares of the conglomerate’s stock worth $353,186,000 after purchasing an additional 1,425,000 shares in the last quarter. Koch Industries Inc. lifted its stake in Danaher by 29,127.3% in the 2nd quarter. Koch Industries Inc. now owns 1,404,665 shares of the conglomerate’s stock worth $1,388,000 after purchasing an additional 1,399,859 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in Danaher by 86.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,011,947 shares of the conglomerate’s stock worth $256,136,000 after purchasing an additional 1,393,165 shares in the last quarter. 76.32% of the stock is owned by institutional investors.

Shares of Danaher Co. (NYSE DHR) opened at $94.00 on Monday. The company has a current ratio of 1.43, a quick ratio of 1.00 and a debt-to-equity ratio of 0.42. The firm has a market cap of $65,386.87, a price-to-earnings ratio of 24.16, a PEG ratio of 2.24 and a beta of 1.02. Danaher Co. has a 52-week low of $77.66 and a 52-week high of $94.82.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Thursday, October 19th. The conglomerate reported $1.00 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.95 by $0.05. Danaher had a net margin of 13.36% and a return on equity of 11.29%. The firm had revenue of $4.53 billion for the quarter, compared to analysts’ expectations of $4.47 billion. During the same quarter last year, the company posted $0.87 EPS. The business’s quarterly revenue was up 9.6% on a year-over-year basis. sell-side analysts expect that Danaher Co. will post 3.99 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be issued a dividend of $0.14 per share. This represents a $0.56 annualized dividend and a dividend yield of 0.60%. The ex-dividend date of this dividend is Thursday, December 28th. Danaher’s dividend payout ratio is currently 16.52%.

In related news, Director Donald J. Ehrlich sold 10,578 shares of the stock in a transaction on Tuesday, October 24th. The shares were sold at an average price of $90.82, for a total transaction of $960,693.96. Following the transaction, the director now owns 104,621 shares of the company’s stock, valued at approximately $9,501,679.22. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Daniel Raskas sold 37,870 shares of the stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $93.33, for a total transaction of $3,534,407.10. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 273,810 shares of company stock worth $25,218,813. 12.20% of the stock is owned by insiders.

Several research firms have issued reports on DHR. Cowen reiterated a “buy” rating and issued a $90.00 target price on shares of Danaher in a research note on Wednesday, October 4th. Morgan Stanley reiterated an “overweight” rating and issued a $95.00 target price (up from $86.00) on shares of Danaher in a research note on Friday, October 6th. Zacks Investment Research upgraded shares of Danaher from a “hold” rating to a “buy” rating and set a $97.00 price objective on the stock in a research report on Thursday, October 5th. Robert W. Baird raised their price objective on shares of Danaher from $87.00 to $97.00 and gave the company an “outperform” rating in a research report on Friday, October 20th. Finally, J P Morgan Chase & Co restated an “overweight” rating and set a $95.00 price objective on shares of Danaher in a research report on Friday, September 8th. One research analyst has rated the stock with a sell rating, four have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. Danaher has a consensus rating of “Buy” and a consensus target price of $94.05.

ILLEGAL ACTIVITY NOTICE: This story was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://sportsperspectives.com/2017/12/18/vident-investment-advisory-llc-invests-417000-in-danaher-co-dhr-stock.html.

Danaher Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply